About 7 results found for searched term "STAT3-IN-17" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49684 | STAT3-IN-17 | STAT |
| STAT3-IN-17 is a moderate STAT3 inhibitor (IC50=0.7 μM; HEK-Blue IL-6), with antiproliferative activity in HeLa cells. | ||
| M8874 | C188-9 | STAT |
| TTI-101 | ||
| C188-9 is a small-molecule STAT3 inhibitor, can block Th2 and Th17 cell expansion and cytokine production to prevent house dust mite (HDM)-induced airway inflammation and remodeling. | ||
| M18434 | Ginkgolic acid 17:1 | PTEN |
| Ginkgolic acid 17:1, a natural product isolated from Ginkgo biloba, inhibits constitutive and inducible STAT3 activation by inducing PTEN and SHP-1 tyrosine phosphatases. In addition, Ginkgolic acid C17:1 has anticancer activity. | ||
| M21677 | Recombinant Human Follistatin 288 (HEK293, C-6His) | Cytokines and Growth Factors |
| FST; follistatin isoform FST317 | ||
| Follistatin 288 is a secreted glycoprotein that was first identified as a follicle-stimulating hormone inhibiting substance in ovarian follicular fluid . Human follistatin 288 cDNA encodes a 317 amino acid (aa) protein with a 29 aa signal sequence, and a 288 aa mature region. Recombinant Human Follistatin/FST is produced by Mammalian expression system and the target gene encoding Gly30-Asn317 is expressed with a 6His tag at the C-terminus. | ||
| M27692 | STAT3-IN-5 | STAT |
| STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC50 value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer. | ||
| M28184 | Debio 0617B | STAT |
| Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors. | ||
| M40707 | Icotrokinra | IL Receptor/Related |
| JNJ-2113; JNJ-77242113; PN-235 | ||
| Icotrokinra (JNJ-77242113, JNJ-2113) is a novel, orally active IL-23R peptide antagonist for studies related to plaque psoriasis. Icotrokinra exhibits high affinity with human IL-23 receptor hIL-23R with a Kd of 7.1 pM. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in PMBCs (IC50=5.6 pM), and inhibits L-23-induced generation of IFNγ and IL-17A in picomolar levels. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
